netFormulary NHS
Southampton Joint Formulary
 Search
 Formulary Chapter 1: Gastro-intestinal system - Full Chapter
01.05.03  Expand sub section  Drugs affecting the immune response
Adalimumab/ adalimumab biosimilar (Humira®, Imraldi®, Amgevita®) (Gastroenterology)
(injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Specify brand.

Severe Crohn’s disease if failed on infliximab

Imraldi and Amgevita are black triangle.

 
Link  NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis after the failure of conventional therapy
   
Golimumab (Simponi®) (Gastroenterology)
(injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

unlicensed unlicensed use in Crohns disease (off licence indication).

 
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
   
Infliximab (Remicade®)(Gastroenterology)
(injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

note Specify brand

 
Link  NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
Link  NICE TA187: Infliximab and adalimumab for the treatment of Crohns disease
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis after the failure of conventional therapy
   
Infliximab biosimilar (Remsima®, Inflectra®, Flixabi®) (Gastroenterology)
(injection)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

note Specify brand.

Flixabi brand is black triangle.

 
Link  NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
Link  NICE TA187: Infliximab and adalimumab for the treatment of Crohns disease
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis after the failure of conventional therapy
   
Ustekinumab (Stelara®) (Gastroenterology)
(injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Link  NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
   
Vedolizumab (Entyvio®)
(intravenous infusion / pre-filled syringe or pen for subcutaneous injection)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

June 2020: Subcutaneous formulation supported by District Prescribing Committee for use as an alternative to IV infusion in eligible patients who meet NICE TA criteria

 
Link  NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Link  NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
   
01.05.03  Expand sub section  Cytokine inhibitors : Treatment of ulcerative colitis and Crohn’s disease
TofacitinibBlack Triangle (XELJANZ®)
(tablets)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine

Traffic Light Status Information

Status Description

Green

Suitable for prescribing by all in both primary and secondary care.  

Amber Recommended

Specialist recommended but suitable for continuation in primary care.  

Amber Initiation

Specialist initiated but suitable for continuation in primary care.  

Amber SCG

Specialist initiated and for continuation in primary care under a locally approved shared care guideline.  

Red

Suitable for prescribing in specialist settings (secondary care) only.   

Red Specialist Centre

Secondary care medicines to be used under specialised commissioning arrangements only.  

Blue

For primary care, either via FP10 or supplied through specialist services. These products may be stocked by hospital pharmacies only for supply to primary care units/wards or for continuing supplies for patients admitted on therapy.  

Black

Not recommended for use.  

netFormulary